Midostaurin (Rydapt): Dosing Essentials in FLT3-Mutated AML and Systemic Mastocytosis

　　Midostaurin(Rydapt;Novartis)is an oral multi-kinase inhibitor active against FLT3,KIT,PDGFR and other kinases.It carries two distinct indications:in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for adults with newly diagnosed AML that is FLT3 mutation–positive as detected by an FDA-approved test;and for adults with aggressive systemic mastocytosis(ASM),systemic mastocytosis with associated hematological neoplasm(SM-AHN)or mast cell leukemia(MCL).The label explicitly states it is not indicated as single-agent induction therapy for AML.

　　The AML indication rests on the phase 3 RATIFY trial(CALGB 10603),which randomized 717 patients with FLT3-mutated AML.Adding midostaurin to standard chemotherapy significantly prolonged overall survival—median 74.7 versus 25.6 months(HR 0.77;P=0.0074),with 4-year survival of 51.4%versus 44.3%.

　　Dosing differs by indication and must not be interchanged.In AML,the recommended dose is 50 mg twice daily with food on days 8 to 21 of each induction cycle and days 8 to 21 of each high-dose cytarabine consolidation cycle.In ASM,SM-AHN and MCL,the dose is 100 mg twice daily with food,continued until disease progression or unacceptable toxicity.

　　Practical administration points matter for consistent exposure:doses should be spaced approximately 12 hours apart,capsules must be swallowed whole and not opened,crushed or chewed,and a missed dose or vomiting should not be replaced—the next dose is taken at the scheduled time.Because midostaurin has moderate emetic potential,prophylactic antiemetics should be given before dosing.

　　Safety monitoring spans the treatment course.Beyond common events such as febrile neutropenia,nausea,mucositis,vomiting and headache,four risks warrant particular attention:pulmonary toxicity,with fatal cases of interstitial lung disease and pneumonitis reported—midostaurin should be discontinued in patients who develop signs or symptoms of ILD or pneumonitis without an infectious etiology;embryo-fetal toxicity,requiring effective contraception during treatment and for at least 4 months after the final dose in patients of reproductive potential;QT prolongation,with ECG assessment advised when coadministered with QT-prolonging drugs;and drug-drug interactions,as strong CYP3A4 inhibitors increase exposure to midostaurin and its active metabolites,and strong inducers should be avoided or replaced with alternative agents.In the mastocytosis population,toxicity should be monitored at least weekly for the first 4 weeks,every other week for the following 8 weeks,and monthly thereafter;hematologic toxicities are managed by interruption and re-escalation from 50 mg twice daily once recovered.